Welcome to our dedicated page for sesn news (Ticker: sesn), a resource for investors and traders seeking the latest updates and insights on sesn stock.
Carisma Therapeutics Inc. (Nasdaq: CARM) is a pioneering clinical-stage biopharmaceutical company headquartered in Philadelphia, PA. The company's primary focus is on the discovery and development of innovative immunotherapies using its proprietary macrophage and monocyte cell engineering platform. Carisma's mission is to create transformative treatments for cancer and other serious diseases.
One of the company's flagship products is CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). CT-0508 is currently being evaluated in a landmark Phase 1 multi-center clinical trial for patients with recurrent or metastatic HER2-overexpressing solid tumors. These tumors do not respond to existing HER2-targeted therapies, making this trial a critical step forward. The trial represents the first time engineered macrophages are being studied in humans and is conducted across seven clinical sites in the U.S., including prominent institutions like the University of Pennsylvania Abramson Cancer Center and the MD Anderson Cancer Center.
In the second quarter of 2023, Carisma achieved a significant milestone by dosing the first patient in the Phase 1 trial of CT-0508 in combination with KEYTRUDA. This achievement underscores Carisma's commitment to advancing the field of engineered macrophages. The company believes it is well-positioned to drive innovation and deliver value to its stakeholders, thanks to its comprehensive and differentiated cell therapy platform.
Financially, Carisma reported having $117.1 million in cash, cash equivalents, and marketable securities as of June 30, 2023. This financial position is expected to sustain the company's planned operations through the end of 2024, providing a solid runway for its ongoing and upcoming projects.
Additionally, Carisma is engaged in various strategic partnerships, research programs, and academic collaborations to further its mission. The company continues to explore new avenues for innovation within its HER2 franchise and across its broader pipeline, aiming for potential value inflection points in the near future.
For more information, visit Carisma's official website at www.carismatx.com.
Sesen Bio (NASDAQ: SESN) has filed proxy materials for a merger with Carisma Therapeutics, scheduled for a stockholder meeting on March 2, 2023. The board recommends voting 'FOR' the merger, citing benefits such as a special cash dividend of approximately
Investor Group owning approximately 8.4% of Sesen Bio urges the Board to hold a stockholder vote regarding the proposed merger with Carisma Therapeutics. The group opposes the merger, questioning the Board's judgment and commitment to stockholders' interests. They demand transparency on Carisma's valuation, incurred fees, and capital investment. The group believes the transaction favors advisors and Carisma at the expense of Sesen Bio's stockholders and calls for an immediate vote to resolve the Board's future.
Sesen Bio reaffirms its commitment to a merger with Carisma Therapeutics, stating it is the best option for stockholder value. Following a four-month review, the Board determined the merger offers an implied value of $0.88 per share after evaluating over 100 companies. The merger includes a special cash dividend of approximately $70 million ($0.34 per share) and a 25.2% ownership stake in the combined company. The Board warns against an alternative proposal from an investor group, citing significant risks and lower potential payouts. The merger aims to deliver immediate cash value and long-term upside to stockholders.
The Investor Group, owning 8.4% of Sesen Bio's common stock (NASDAQ: SESN), opposes the proposed merger with Carisma Therapeutics, deeming it value-destructive. They argue that Sesen Bio's $140 million cash reserve should be returned to shareholders, equating to $0.70 per share, a 15% premium. The Group criticizes the management's valuation of Carisma, particularly in light of a 30%-60% decline in comparable biotech firms. They demand an updated fairness opinion and have proposed terms including a $100 million cash dividend to support the merger.
Sesen Bio stockholders are set to receive a special cash dividend of approximately
Sesen Bio announced a proposed merger with Carisma Therapeutics, focusing on advancing engineered macrophages for cancer treatment. The transaction is anticipated to close in 2-3 months, pending shareholder approval. Sesen Bio stockholders will own approximately 41.7% of the new entity. Sesen reported a third-quarter revenue of $40 million due to the Roche Asset Purchase Agreement, with a net income of $20.5 million. However, net income has decreased significantly from $71.7 million in Q3 2021, mainly due to higher restructuring charges and unfavorable non-cash expenses.
Sesen Bio has announced a definitive merger agreement with Carisma Therapeutics to create a clinical-stage biotechnology company focusing on engineered macrophages for cancer treatment. The combined entity is expected to have around
Sesen Bio (SESN) announced Q2 2022 results, reporting a net loss of $32 million or $0.16 per share. The company has paused clinical development of its lead asset, Vicineum™, and is focusing on assessing strategic alternatives to maximize shareholder value. As of June 30, 2022, Sesen Bio has a strong cash position of $161.2 million. R&D expenses surged to $29.9 million compared to $7.2 million in Q2 2021, primarily due to the write-off of unutilized resources. General and administrative expenses also rose significantly, driven by legal settlements.
Sesen Bio has announced a strategic pause in the US development of its lead asset, Vicineum, for treating non-muscle invasive bladder cancer (NMIBC). This decision follows a detailed reassessment of the associated costs and regulatory requirements for an additional Phase 3 clinical trial after discussions with the FDA. The company aims to conserve cash and is seeking a partner for further development of Vicineum while exploring potential strategic alternatives to enhance shareholder value. As of June 30, 2022, Sesen Bio reported $161.2 million in cash.
Sesen Bio (Nasdaq: SESN) reported its Q1 2022 results, highlighting a robust cash position of $169.8 million, expected to fund operations into Q4 2024. The company is navigating regulatory pathways for a potential BLA resubmission for Vicineum™ to treat non-muscle invasive bladder cancer. Significant milestones include a $20 million payment from Roche under a licensing agreement, totaling $50 million in cumulative payments. Despite a net loss reduction to $0.8 million from $55.5 million year-over-year, G&A expenses rose due to legal costs and increased headcount.
FAQ
What is the market cap of sesn (sesn)?
What is Carisma Therapeutics Inc.?
What is CT-0508?
What recent milestones has Carisma achieved?
Where is Carisma conducting its Phase 1 clinical trials?
What is Carisma's financial outlook?
What makes Carisma's cell therapy platform unique?
What is the significance of the HER2 receptor in Carisma's research?
How does Carisma plan to deliver stakeholder value?
What partnerships and collaborations is Carisma involved in?